Patents by Inventor Jacqueline D. Hicks
Jacqueline D. Hicks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416227Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: September 9, 2021Publication date: December 28, 2023Applicant: Merck Sharp & Dohme LLCInventors: Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Maoqun Tian, Salman Jabri, Galen Paul Shearn-Nance, Rongze Kuang, Zhiqiang Zhao, Zhicai Wu
-
Publication number: 20230348428Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: July 6, 2021Publication date: November 2, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jacqueline D. HICKS, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
-
Publication number: 20230286958Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: June 10, 2021Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
-
Publication number: 20230167085Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.Type: ApplicationFiled: May 7, 2021Publication date: June 1, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jacqueline D. HICKS, John S. Debenham, Amjad Ali, Ying-Duo Gao, Lan Wei, Dexi Yang, Rongze Kuang, Alan Hruza, Peter Nizner, Daniel A. Tatosian
-
Publication number: 20230147170Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.Type: ApplicationFiled: March 26, 2021Publication date: May 11, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jacqueline D. Hicks, Amjad Ali, John S. Debenham, Anthony Donofrio, Wenlang Fu, Ying-Duo Gao, Alan Hruza, Yeon-Hee Lim, Matthew J. Lombardo, Peter Nizner, Sung-Sau So, Zheng Tan, Daniel A. Tatosian, Dong Xiao, Dexi Yang, Yang Yu
-
Publication number: 20220235033Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.Type: ApplicationFiled: May 26, 2020Publication date: July 28, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Jacqueline D. Hicks, John S. Debenham, Amjad Ali, Lan Wei, Tianying Jian, Dexi Yang, Anthony K. Ogawa, Wenlang Fu, Matthew Lombardo, Rongze Kuang, Meng Yang, Sung-Sau So, Kenneth Ellsworth, Peter Nizner, Daniel A. Tatosian, Robert R. Wilkening, Jun Wang
-
Patent number: 11014920Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: GrantFiled: November 13, 2017Date of Patent: May 25, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Jacqueline D. Hicks, Brian Alexander McKittrick, Brent R. Whitehead, Matthew Lombardo, Xiaoqing Han, Jerry A. Taylor, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu
-
Patent number: 10875851Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: GrantFiled: November 13, 2017Date of Patent: December 29, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
-
Publication number: 20200262831Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: ApplicationFiled: November 13, 2017Publication date: August 20, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Jacqueline D. Hicks, Brian Alexander McKittrick, Brent R. Whitehead, Matthew Lombardo, Xiaoqing Han, Jerry A. Taylor, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu
-
Publication number: 20190352294Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.Type: ApplicationFiled: November 13, 2017Publication date: November 21, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
-
Patent number: 9868733Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 19, 2013Date of Patent: January 16, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan
-
Patent number: 9540364Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 15, 2013Date of Patent: January 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Patent number: 9527839Abstract: Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 15, 2013Date of Patent: December 27, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Patent number: 9382243Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 16, 2013Date of Patent: July 5, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Patent number: 9290517Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 19, 2013Date of Patent: March 22, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Troy McCracken, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Publication number: 20150284411Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: August 19, 2013Publication date: October 8, 2015Inventors: James M. Apgar, Ashok Arasappan, Tesfaye Biftu, Ping Chen, Danqing Feng, Erin Guidry, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Troy McCracken, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Publication number: 20150218149Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: August 15, 2013Publication date: August 6, 2015Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Publication number: 20150210685Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: August 16, 2013Publication date: July 30, 2015Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu
-
Publication number: 20150203487Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: August 19, 2013Publication date: July 23, 2015Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan
-
Publication number: 20150197516Abstract: Novel compounds described herein are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: August 15, 2013Publication date: July 16, 2015Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu